Radiography
Volume 12, Issue 3 , Pages 203-208 , August 2006

The role of stem cell transplantation in the management of Non-Hodgkin's lymphoma

  • Irene Foster

      Affiliations

    • Corresponding Author InformationTel.: +44 1793 785752; fax: +44 1793 785774.

Received 21 January 2005 ,Accepted 21 June 2005.

References 

  1. Souhami R, Tobias J. Cancer and its management. 3rd ed.. Blackwell Science; 1998;
  2. Bolwell BJ. Autologous bone marrow transplantation for Hodgkin's disease and non-Hodgkin's lymphoma. Semin Oncol. 1994;21(4):86–95
  3. Gratwohl A, Hermans J. Indications and donor source of hematopoietic stem cell transplants in Europe 1993: EBMT Report. Clin Transpl. 1995;9:355–363
  4. Nademanee A, Schmidt GM, O'Donnell MR, Snyder OS, Parker PA, Stein A, et al. High dose chemotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor risk aggressive lymphoma. Blood. 1992;80:1130–1139
  5. Applebaum FR, Sullivan KM, Buckner CD. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol. 1987;5:1340–1347
  6. Lopez-Guillermo A, Monserrat E, Reverter JC, Cervantes F, Escoda L, Tassies D, et al. Large cell lymphoma: a study of prognostic factors and assessment of five recently proposed predictive systems. Leuk Lymphoma. 1993;10(1–2):101–109
  7. Schultze JL, Gribben JG. Minimal residual disease in non-Hodgkin's lymphoma. Biomed Pharmacother. 1996;50:451–458
  8. Stone RM, Neuberg D, Soiffer R, Takovian T, Whelan M, Rabinowe SN, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994;12(12):2535–2542
  9. Gulatti SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin's disease. Ann Int Med. 1992;116:183–189
  10. Thomas ED. Stem cell transplantation: past, present and future. Arch Immunol Ther Exp. 1997;451–455
  11. Williams CD, Goldstone AH, Pearce RM, Philip T, Hartmann O, Colombat P, et al. Purging of bone marrow in autologous bone marrow transplantation of non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol. 1996;14:2454–2464
  12. Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo M, et al. Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Marrow Transplant Registry. Blood. 2004;104(12):3797–3803
  13. Escalon MP, Champlin RE, Saliba RM, Acholonu SA, Hosing C, Fayad L, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol. 2004;22(12):2419–2423
  14. Khouri IF, Lee MS, Saliba RM, Jun G, Fayad L, Younes A, et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol. 2003;21(23):4407–4412
  15. Bishop MR. The graft-versus-lymphoma effect: fact, fiction of opportunity?. J Clin Oncol. 2003;21(20):3713–3715
  16. Toren A, Rechavi G, Nagler A. Early fulminant leukemia post autologous bone marrow transplantation in non-Hodgkin's lymphoma patients. Med Oncol. 1998;15:109–112
  17. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y. Cytokines in cancer immunity and immunotherapy. Immunol Rev. 2001;202:275–293
  18. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet. 2000;356:1795–1799
  19. Krishnan A, Bhatia S, Slovak ML, Arber DA, Niland JC, Nademanee A, et al. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood. 2000;95(5):1588–1593
  20. Friedberg JW, Neuberg O, Stone RM, Alyea E, Jallow H, LaCasce A, et al. Outcome in patients with myeloplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999;17(10):3128–3135
  21. Miller JS, Arthur DC, Litz CE, Neglia JP, Miller WJ, Weisdorf OJ. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood. 1994;83(12):3780–3786
  22. Darrington DL, Vose JM, Anderson JR, Bierman PJ, Bishop MR, Chan WC, et al. Incidence and characterisation of secondary myelodysplasic syndrome and acute myelogenous leukaemia following high dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12(12):2527–2534
  23. Milligan OW, de Elvira CR, Kolb HJ, Goldstone AH, Meloni G, Rohatiner AZ, et al. Secondary leukaemia and myelodysplasia after autografting for lymphoma: results from the EBMT. Br J Haematol. 1999;106:1020–1026
  24. Baker KS, DeFor TE, Burns LJ, Ramsay NK, Neglia JP, Robison LL. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21(7):1352–1358
  25. Straus OJ. Treatment of Burkitt's lymphoma in HIV-positive patients. Biomed Pharmacother. 1996;50:447–450
  26. Tulpule A, Levine A. AIDS-related lymphoma. Blood Rev. 1999;13:147–150
  27. Northfelt OW, Kaplan LD. Clinical manifestations and treatment of HIV related non-Hodgkin lymphoma. Cancer Surv. 1991;10:121–133

PII: S1078-8174(05)00107-0

doi: 10.1016/j.radi.2005.06.005

Radiography
Volume 12, Issue 3 , Pages 203-208 , August 2006

Article Tools